OncoResponse, a Houston, Texas–based immuno-oncology antibody discovery company, raised approx. $3.5m and closed a $22.5m Series A financing.
Backers included HT Family Office, which joined Arch Venture Partners, Canaan Partners, and MD Anderson, Marsh Rice University, Alexandria Real Estate Equities, Baxalta, GreatPoint Ventures and the Helsinn Investment Fund.
The company, which had previously announced Series A round raises of $7M in October 2016 and of $12.5m in May 2016, will use the funds for its ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
Led by Clifford J. Stocks, CEO, OncoResponse utilizes a clinically validated platform technology to screen antibodies made by the human immune system and identify those with better reactivity to cancer. The company has a strategic alliance with MD Anderson Cancer Center, which provides access to patient samples across multiple cancer indications and to oncology and translational medicine expertise including clinical and regulatory input.
In conjunction with the funding, OncoResponse has also appointed Mike Gallatin, Ph.D., Albert Yu, M.D., and Elizabeth Jaffee, M.D. to its Scientific Advisory Board (SAB), who will join original members James Welsh, M.D. and David Hong, M.D., both investigators at MD Anderson Cancer Center. Kristine Swiderek, Ph.D., CSO of OncoResponse, is chair of the SAB.